Medtronic's next-generation renal denervation (RDN) catheter — developed for transradial access — now has a name, GM Jason ...
Medtronic reached a critical juncture last month in its quest to build the market for renal denervation, a new device-based ...
Medtronic’s stock narrative has recently shifted, as reflected in a modest rise in the consensus analyst price target from ...
Patients treated with Symplicity Spyral had significantly lower blood pressure than people who received a sham treatment ...
Medtronic (NYSE:MDT) underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, ...
On August 19th, Medtronic released its earnings report for the fiscal first quarter ended July 25th, 2025. The company's ...
With its stock down 4.5% over the past month, it is easy to disregard Medtronic (NYSE:MDT). To decide if this trend could ...
After joining Medtronic as its first chief innovation officer in 2023, SVP Ken Washington says he's leaving on Nov. 14 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback